Added to YB: 2026-06-11
Pitch date: 2026-06-09
DTIL [bullish]
Precision BioSciences, Inc.
-5.29%
current return
Author Info
Triple S is a professional special situations investor who shares ideas in their newsletter. Sign up for the newsletter.
Company Info
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
Market Cap
$177.0M
Pitch Price
$6.81
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.52
P/E
-2.57
EV/Sales
2.31
Sector
Biotechnology
Category
growth
Free Demo of New Special Situations Tool and Stock Trade Compilation Episode Ocho - $DTIL
DTIL: Clinical-stage gene editing biotech on ARCUS platform (insertion/elimination/excision). $126M cash funds runway to 2028, de-risking execution. PBGENE-HBV enrolling in ELIMINATE-B trial; PBGENE-DMD secured FDA Fast Track + dosing in Phase 1/2 FUNCTION-DMD. Likes setup, decent covered calls.
Read full article (1 min)